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Background: A clinical test that could inform the clinician about the severity of a patient's 
nasal symptoms and health-related quality of life (QOL ) would be very useful. 
Objective: We attempted to determine whether, in patients with perennial allergic" rhinitis, 
nasal challenge with histamine could be used to estimate daily symptoms and QOL. 
Methods: Forty-eight patients with perennial allergic rhinitis were challenged with histamine 
to determine nasal hyperreactivity. Nasal response was monitored by the number of sneezes, 
the amount of secretion, and a symptom score. Daily nasal symptoms were recorded uring 
the 2 preceding weeks. Patients also completed a rhinitis QOL questionnaire. 
Results: Responsiveness to histamine and total daily nasal symptoms were moderately 
correlated (r = 0.51, p = 0.00I). Comparison of total daily nasal symptoms with the overall 
QOL score showed a moderate correlation (r = 0.59, p < 0.001). Nasal response to 
histamine and overall QOL score were also correlated (r = 0.43, p = 0.002). However, 
overall QOL and daily nasal symptoms could be predicted by wide 95% confidence intervals 
only for each decade of nasal responsiveness to histamine (expressed as a composite symptom 
score). 
Conclusion: In patients with perennial allergic rhinitis nasal hyperreactivity as determined by 
histamine challenge, QOL, and daily nasal symptoms are moderately correlated. Therefore 
nasal histamine challenge can be used as a tool for estimating the severity of daily nasal 
symptoms and QOL, although it cannot predict nasal symptoms and QOL very accurately. 
(J Allergy Clin Immunol 1996;98:508-13.) 
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Patients with allergic rhinitis experience sneez- 
ing, nasal itchiness, rhinorrhea, and nasal blockage 
after exposure to the relevant allergen. After re- 
peated exposure to allergen, nasal responsiveness 
to allergens increases. This phenomenon, known 
as nasal priming, was first described by Connell I 
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Abbreviation used 
QOL: Quality of life 
and was confirmed by others. 2, 3 Exposure to aller- 
gen also increases nasal responsiveness to nonspe- 
cific stimuli. 4This nonspecific nasal hyperreactivity 
is particularly important in patients with perennial 
allergic rhinitis, because they are continually ex- 
posed to allergen. 
Hyperreactivity can be described as a clinical 
feature characterized by occurrence of symp- 
toms on exposure to daily-life stimuli as esti- 
mated by history (clinical hyperreactivity). De- 
termination of nasal hyperreactivity by nasal 
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provocation tests with pharmacologic or physical 
agents assumes a relationship between this form 
of nasal hyperreactivity and hyperreactivity as 
estimated by history. Gerth van Wijk et al. 5 
demonstrated that the amount of secretion and 
the number of sneezes in response to histamine 
challenge were associated with the clinical hy- 
perreactivity assessed by a hyperreactivity score. 
The importance of routine histamine chal- 
lenges in daily practice is not clear. In a previous 
study we showed that assessment of nasal airway 
resistance after histamine challenge is less ap- 
propriate in distinguishing patients from healthy 
subjects in terms of reproducibil ity and estima- 
tion of clinical hyperreactivity compared with 
assessment of number of sneezes and amount of 
secretion. 6 Recently, we demonstrated that reac- 
tivity to histamine expressed as area under the 
curve with a composite symptom score (accord- 
ing to the method of Lebel et al. 7) as response 
variable is a valid method for detecting treatment 
effect. 8 In addition, the method is valid for distin- 
guishing between patients with and without a late- 
phase allergic reaction. 9 Moreover, this method ap- 
pears to be reproducible? ° 
Recently, a correlation between daily symp- 
toms and response to histamine challenge was 
demonstrated in patients with nonallergic nasal 
hyperreactivity, t~ We attempted to determine 
whether, in patients with perennial allergic rhi- 
nitis, nasal hyperreactivity (responsiveness to 
histamine) corresponds with daily nasal symp- 
toms. In addition to the amount of secretion and 
the number of sneezes, the symptom score of Lebel 
et al. 7 was used to monitor the nasal responsiveness 
to histamine. 
Patients' nasal symptoms also interfere with 
their day-to-day lives. To measure the influence of 
nasal symptoms on day-to-day life, rhinitis quality 
of life (QOL) questionnaires have been devel- 
oped. ~2-~4 Juniper et al. 12,13 demonstrated that 
QOL deteriorated after allergen exposure (pollen 
season) and increased after symptomatic treatment. 
We performed this study to determine whether, 
in patients with perennial allergic rhinitis, the daily 
nasal symptoms are correlated with QOL and also 
whether nasal hyperreactivity, as measured by na- 
sal histamine challenge, is correlated with QOL 
scores and nasal symptoms. Furthermore, we at- 
tempted to determine whether nasal histamine 
challenge can be used as a tool to estimate the 
severity of patients' daily nasal symptoms and 
health-related QOL. 
METHODS 
Study design 
Each adult patient with perennial allergic rhinitis 
visiting our outpatient clinic for the first time completed 
a nasal symptom diary during the 2 weeks preceding the 
follow-up visit. At this second visit, patients completed a 
rhinitis QOL questionnaire and underwent a nasal his- 
tamine challenge. 
Subjects 
Forty-eight patients (23 men and 25 women; mean 
age, 30 _+ 10 years) with a history of perennial rhinitis 
participated in this study. They had to meet the follow- 
ing criteria: perennial rhinitis for at least i year; positive 
intradermal skin test response to at least one perennial 
allergen (house dust mites and/or molds and/or animal 
dander; ALK Benelux, Groningen, The Netherlands) 
and exposure to the allergen(s) involved. Of the patients 
included, 38 were allergic to house dust mites, seven 
were allergic to house dust mites and pets (and had a pet 
at home), two were allergic to their pets only, and one 
was allergic to molds. Patients with a concomitant 
allergy to pollen were only included outside the pollen 
season. During the study they were not permitted to use 
any medication affecting nasal symptoms, apart from 
Acrivastine, 8 rag, (as rescue medication). Acrivastine 
had to be withdrawn 3 days before the histamine chal- 
lenge. Patients with a nasal infection were excluded. 
Nasal symptom diary 
Patients recorded their nasal symptoms for 2 weeks on 
a modified diary card according to the symptom score 
system of Norman et al. 15 Sneezes/itching nose, nasal 
blockage, and rhinorrhea were scored according to their 
daily duration (0 = no symptoms, 1 = symptoms < 1 
hour, 2 = symptoms between 1 and 4 hours, 3 = 
symptoms > 4 hours). The sum of the individual symp- 
toms during the 2 weeks and the total nasal symptom 
score (sneezing/itchiness + rhinorrhea + nasal block- 
age) during these 2 weeks were used for statistical 
analysis. 
Rhinitis QOL questionnaire 
We translated the rhinitis QOL questionnaire devel- 
oped by Juniper et al. 13 to Dutch. Patients had to score 
25 items subdivided into the following domains: sleep (n 
= 3), nasal symptoms (n = 5), practical problems (n = 
3), emotions (n = 4), activities (n = 3), and nonrhinitis 
symptoms (n = 7). In each item, they were asked how 
much they were troubled as a result of their nasal 
symptoms during the previous week. The score of these 
items ranged from 0 (not troubled) to 6 points (extreme- 
ly troubled). In case of the items concerning emotions, 
patients were asked how often they were troubled, in 
each of the items, as a result of their nasal symptoms. 
The score also ranged from 0 (never troubled) to 6 
points (constantly troubled). In the analysis the mean 
within-patient score of each QOL domain was used 
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TABLE I. Nasal hyperreact iv i ty  versus daily 
nasal symptoms (n = 40) 
Nasal hyperreactivity 
Daily nasal Sneezes Secretion Symptom score 
symptoms (r) (r) (r) 
Itchiness/sneezing 0.00 0.22 0.49* 
Secretion 0.04 0.41" 0.39* 
Congestion 0.14 0.05 0.31' 
Total symptoms 0.10 0.24 0.51" 
r, Spearman's correlation coefficient. 
Up < 0.05. 
(these mean domain scores were measured by calculat- 
ing the mean of the items within each domain). In 
addition, the total score of the means of the six domains 
was used to calculate the overall QOL score. 
Nasal h is tamine chal lenge 
Challenges were performed according to the methods 
described by Gerth van Wijk et al. 5, 6 Patients waited for 
half an hour before the test to allow the nasal mucosa 
time to acclimatize. Nasal challenge with histamine 
phosphate (0.25, 0.5, 1.0, 2.0, and 4.0 mg/ml) was 
performed at 5-minute intervals after challenge with 
phosphate-buffered saline. The phosphate-buffered sa-
line and the increasing doses of histamine were sprayed 
into the nostrils with a nasal pump spray, delivering a
fixed dose of 0.125 ml of solution. After each challenge, 
the symptom score 7was recorded, sneezes were counted, 
and anterior rhinorrhea was measured by collecting 
nasal secretions in a syringe-equipped funnel? c' The 
areas under the curve of histamine dose response were 
used in the statistical analysis. 
Symptom score 
The symptom score according to Lebel et al. 7 was 
used: three to four sneezes = 1 point, five or more 
sneezes = 3 points, anterior rhinorrhea = 1 point, 
posterior hinorrhea = 1 point, difficult nasal breath- 
ing = 1 point, one nostril blocked = 2 points, both 
nostrils blocked = 3 points, pruritus of the nose = 1 
point, pruritus of the palate or ear = 1 point, and 
conjunctivitis = 1 point. Total score ranged from 0 to 11 
points. 
Stat ist ics 
Forty patients completed their nasal symptom diary 
correctly; in comparing nasal symptoms with QOL 
scores and nasal hyperreactivity, we used data of these 
patients only (n = 40). When the correlation between 
QOL scores and nasal hyperreactivity was tested, data 
from all subjects could be used (n = 48). 
Because not all variables were normally distributed, 
relationships between the variables were tested by 
Spearman's rank correlation. A two-tailedp value of less 
than 0.05 was considered significant. Furthermore, the 
TABLE II. QOL versus nasat hyperreact iv i ty  
(n = 48) 
QOL domain Nasal hyperreactivity 
Sneezes Secretion Symptom score 
(d (r} (r) 
Sleep 0.15 0.36* 0.27 
Nonrhinitis ymptoms 0.28 0.34* 0.29* 
Practical problems 0.10 0.25 0:34* 
Nasal symptoms 0.26 0.18 0.47* 
Activities 0.37* 0.21 0.32* 
Emotions 0.07 0.16 0:24 
Overall QOL 0.31" 0.32* 0.43* 
r, Spearman's correlation coefficient. 
*p < 0.05. 
mean predicted values and 95% confidence intervals of 
the overall QOL score and total nasal symptoms for each 
decade of nasal response to histamine challenge were 
determined by multiple regression analysis (this method 
could be used because these three variables were nor- 
mally distributed). 
RESULTS 
Table I shows correlat ion coefficients of daily 
nasal symptoms compared with nasal response to 
histamine. Histamine responsiveness is expressed 
as the area under the curve of the amount of 
secretion, the number of sneezes, and the symptom 
score of Lebet et al. 7 after nasal histamine chal- 
lenge. Moderate  but statistically significant corre- 
lations were found between the daily symptoms 
and histamine responsiveness, expressed as symp- 
tom score of Lebel  et al. 7 The secretory response 
to histamine is moderate ly  correlated with daily 
secretion only. When histamine responsiveness 
was expressed as the number  of sneezes, no corre- 
lations were foun& 
Table I I  shows the correlat ion coefficients of 
nasal response to histamine and QOL domains. 
The symptom score of Lebel  et al. 7 correlates 
moderate ly  with most QOL domains, with the 
exceptions of sleep and emotions. However,  the 
correlat ions with sleep and emotions tended to be 
significant (r = 0.27, p = 0.067 and r = 0:24, p = 
0.098, respectively). The number of sneezes is 
corre lated with the activities and with overall  QOL 
score only. Secretory response to histamine is 
correlated with sleep, nonrhinit is symptoms, and 
the overall  QOL score. 
When total daily nasal symptoms are compared 
with the QOL domains, moderate  but statistically 
significant correlat ions are shown for all QOL 
domains and the overall  QOL score (Table I I I).  Of  
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TABLE ill. QOL versus daily nasal symptoms (n = 40) 
QOL domain 
Daily nasal symptoms 
Itchiness/sneezing (r) Secretion (r) Congestion {r) Total (r) 
Sleep 0.33" 0.25 0.29 0.35" 
Nonrhinitis ymptoms 0.37* 0.19 0.29 0.36* 
Practical problems 0.57* 0.37* 0.39* 0.56* 
Nasal symptoms 0.61" 0.43* 0.23 0.54* 
Activities 0.46" 0.14 0.52* 0.45" 
Emotions 0.29 0.19 0.36* 0.36* 
Overall QOL 0.59* 0.36* 0.47* 0.59* 
r, Spearman's correlation coefficient. 
*p < 0.05. 
the individual symptoms, itchiness/sneezing s cor- 
related with five of the six QOL domains and the 
overall QOL, congestion with three domains and 
the overall QOL, and secretion with two domains 
and the overall QOL only. Because of the within- 
patient variability of the daily symptoms, the p 
values might be too optimistic. 
When daily acrivastine intake was added to the 
total score of the diary, as Norman et al. ~5 did, the 
correlation coefficients of total daily symptoms 
with hyperreactivity were 0.05 (sneezes), 0.26 (se- 
cretion), and 0.51 (symptom score) compared with 
0.10, 0.24, and 0.51 without addition of acrivastine. 
Correlations of total daily symptoms with QOL 
domains ranged from 0.37 to 0.60 compared with 
0.35 to 0.59 with or without acrivastine, respec- 
tively. So acrivastine intake did not change the 
correlation coefficients. In Fig. t the association 
between overall QOL and total daily symptoms i
shown (r = 0.59, p < 0.001). 
In Table IV predicted values of and 95% confi- 
dence intervals for each decade of nasal response 
to histamine are demonstrated. Nasal response to 
histamine xplained 21% of the variance of nasal 
symptoms and 21% of the variance of QOL. 
DISCUSSION 
We attempted to determine whether routine 
nasal histamine challenges in patients with peren- 
nial allergic rhinitis can be used to give an impres- 
sion of the severity of patients' daily nasal symp- 
toms. Nasal response to histamine, if expressed as 
the symptom score of Lebel et al., 7 correlated 
moderately with sneezes/itchiness, rhinorrhea, 
congestion, and total nasal symptoms. Secretory 
response to histamine correlated only weakly with 
nasal symptoms, whereas the number of sneezes in 
response to histamine challenge was not correlated 
with daily nasal symptoms at all. This is in contrast 
to a previous tudy by Gerth van Wijk et al., 5 who 
demonstrated that histamine-induced sneezes and 
secretion correlated well with daily nasal symp- 
toms. However, the diary they used contained, 
besides the symptom score system of Norman et 
al., !5 specific questions about nasal hyperreactivity, 
so the two diaries are not completely comparable. 
This might suggest hat routine histamine chal- 
lenges in daily practice, if monitored by the 
symptom score of Lebel et al., 7 give a better 
impression of the severity of patients' daily 
symptoms. The correlations, however, were not 
very strong, and daily nasal symptoms could be 
predicted by wide 95% confidence intervals only. 
One clinical test cannot be expected to exactly 
predict daily nasal symptoms. However, it might 
be used in addition to a carefully taken history to 
make a better estimation of the severity of 
patients' symptoms. 
Patients with rhinitis may have nasal symptoms 
that adversely affect their day-to-day lives. We 
used the rhinitis QOL questionnaire d veloped by 
Juniper et al. 13 to measure the effect of rhinitis on 
day-to-day life. Juniper et al. lz, 13 have validated 
this questionnaire and have shown that it is a 
useful instrument in clinical trials to detect within- 
subject changes over time (treatment effect, aller- 
gen exposure). We did not study changes in QOL, 
but we attempted to determine whether QOL 
scores are correlated with the daily nasal symptoms 
and nasal response to histamine. 
Malo et al. 17 demonstrated that in patients with 
asthma, QOL and bronchial hyperreactivity were 
correlated. Because the relationship between asal 
hyperreactivity and QOL has not been studied yet, 
we investigated whether in patients with perennial 
allergic rhinitis, such a relationship could also be 
demonstrated. Nasal hyperreactivity was deter- 
mined by nasal response to histamine. When his- 
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FIG. 1. Overall QOL score plotted against total daily nasal 
symptoms recorded during 2 weeks (n = 40). 
tamine responsiveness was expressed as the symp- 
tom score, significant correlations were found with 
all QOL domains, with the exceptions of emotions 
and sleep. The correlation coefficients found in our 
rhinitis study were moderate (0.24 < r < 0.47); 
however, they were equal to or higher than those in 
asthma studies. Correlation coefficients between 
bronchial responsiveness to methacholine found 
by Malo et al. iv ranged from -0.1 to -0.24. Marks 
et al. is studied the relationship between changes in 
bronchial hyperreactivity and changes in QOL; 
correlation coefficients ranged from 0.14 to 0.47. 
The number of sneezes and the amount of secre- 
tion in response to histamine challenge correlated 
only slightly with some of the QOL domains. So 
when nasal hyperreactMty is compared with QOL, 
nasal hyperreactivity expressed as the symptom score 
of Lebel et al. 7 is a better variable than the number of 
sneezes and/or the amount of secretion. 
When QOL was compared with nasal symptom 
diaries, all QOL scores were correlated with total 
nasal symptoms, indicating that in patients with more 
severe rhinitis symptoms, QOL is more impaired. 
The moderate correlations between asal symptoms 
and the nasal symptom domain of QOL might be due 
to the indMdual perception of the degree of impair- 
ment caused by the nasal symptoms. Some patients 
might be impaired by only a few nasal symptoms, 
whereas others might be less impaired by more 
TABLE IV. Predicted nasal symptoms (n = 
40) and QOL (n = 48) for each decade of the 
hyperreactivity range 
Predicted nasal Predicted 
Hyperreact ivity symptom score QOL score 
symptom 
score Mean 95% CI Mean 95% CI 
10 34.98 0.00-88:34 1.43 0.00-3.44 
20 48.46 0.00-100.79 L89 0.00-3.88 
30 61.94 0.31-114.57 2.36 0.37-4.35 
40 75.42 2L19-129.65 2.81 0.79-4.85 
50 88.90 31.88-145.93 3.29 1.18-5.39 
CI, Confidence interval. 
severe nasal symptoms. The correlation coefficients 
(0.35 to 0.59) we found are about in the same range 
as those found by Juniper and Guyatt 12 (0.31 to 0.59); 
however, the results are not totally comparable, 
because Juniper and Guyatt compared changes in 
nasal symptoms with changes in QOL. 
When QOL scores were compared with the 
individual nasal symptoms, a better correlation was 
seen with sneezes/itchiness than with rhinorrhea 
and congestion, so that it seems that sneezing/ 
itchiness causes the most impairment of day-to-day 
life. Perhaps patients become used to having stuffy 
noses and blowing their noses, but sneezing and 
nasal itchiness are hard to ignore and more difficult 
to accept. Because the Dutch version of the rhinitis 
QOL questionnaire developed and validated by 
Juniper et al. 13 was correlated with daily nasal 
symptoms, it can also be used in the Netherlands as 
a valid tool to measure rhinitis QOL. 
When acrivastine intake was added to the total 
nasal symptoms, as Norman et al. t5 did, the corre- 
lations between total nasal symptoms and QOL or 
responsiveness to histamine challenge did not 
change. So it seems to make no difference whether 
acrivastine intake is included or not. Norman et 
al. is also found that using the symptom diary to 
interpret he clinical effectiveness of immunother- 
apy made no difference, whether the use of anti- 
histamines was included or not. 
In conclusion, in patients with perennial allergic 
rhinitis nasal hyperreactivity, QOL, and daily nasal 
symptoms are moderately correlated. Therefore 
routine histamine challenge, if expressed by a 
composite symptom score, can be used as tool to 
obtain an impression of daily nasal sYmptoms and 
rhinitis QOL, although it cannot predict nasal 
symptoms and QOL very accurately. 
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